Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Non-metastatic
Is any hormonal monitoring necessary for males with breast cancer on adjuvant aromatase inhibitor and LHRH agonist (Lupron)?
Related Questions
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What are your top takeaways in Medical Oncology from SABCS 2024?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/Her2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
With the recent FDA approval of adjuvant ribociclib, how are you deciding between ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?
What are your top takeaways in Radiation Oncology from SABCS 2024?
Do you routinely check hormone levels to confirm postmenopausal status before adding aromatase inhibitors to OFS in premenopausal women with early breast cancer?
What are your top takeaways in Breast Cancer from ASTRO 2024?
